UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-...

Descripción completa

Detalles Bibliográficos
Autores principales: Roddick, Alistair J., Wonnacott, Alexa, Webb, David, Watt, Angela, Watson, Michael A., Staplin, Natalie, Riding, Alex, Lioudaki, Eirini, Kuverji, Apexa, Kossi, Mohsen El, Holmes, Patrick, Holloway, Matt, Fraser, Donald, Carvalho, Chris, Burton, James O., Bhandari, Sunil, Herrington, William G., Frankel, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598949/
https://www.ncbi.nlm.nih.gov/pubmed/37880609
http://dx.doi.org/10.1186/s12882-023-03339-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598949/
https://www.ncbi.nlm.nih.gov/pubmed/37880609
http://dx.doi.org/10.1186/s12882-023-03339-3

Ejemplares similares